Advances in the treatment of systemic lupus erythematosus: From back to the future, to the future and beyond

Felten, Renaud; Scher, Florence; Sibilia, Jean; Chasset, François; Arnaud, Laurent

doi:10.1016/j.jbspin.2018.09.004

Cited by 29 publications

(19 citation statements)

References 63 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Furthermore, cumulative corticosteroids dose has been related with a higher damage accrual and cardiovascular impairments, being both of them, the main causes of mortality in late stages of SLE disease. 3,23,24…”

Section: Discussionmentioning

confidence: 99%

Trends in mortality from lupus in Spain from 1980 to 2018

Hernández‐Rodríguez

Durán‐Romero

Jiménez

et al. 2020

Lupus

View full text Add to dashboard Cite

Background Recent studies suggest that Systemic lupus erythematosus (SLE) mortality rates in Spain are decreasing. However, SLE mortality in Spain has been poorly studied. The purpose of study is to assess the temporal trends of mortality rates in the Spanish population with SLE from 1980 to 2018. Methods Death records and mid-year population data were collected from the National Statistics Institute. Age-standardized mortality rates were calculated for overall population and for each sex and age group. Significant changes in mortality trends were identified by Joinpoint regressions. Also, an Age-period-cohort (APC) and Potential Years of Life Lost (PYLL) analysis was carried out to know the burden of SLE disease. Results The overall SLE mortality rates in Spain has experimented an increased through the last 39 years. Mortality rates from the period 1980–1984 was 0.83 per 1.000.000 inhabitants, reaching the value to 1.77 cases per 1.000.000 from the period 2014–2018. A decreasing trend has been observed since 1999. Conclusions SLE mortality rate has increased in Spain between 1980 and 1999, with a sustained decrease up to our days.

show abstract

Section: Discussionmentioning

confidence: 99%

Trends in mortality from lupus in Spain from 1980 to 2018

Hernández‐Rodríguez

Durán‐Romero

Jiménez

et al. 2020

Lupus

View full text Add to dashboard Cite

show abstract

“…Commonly prescribed anti-inflammatory drugs include Metformin, non-steroidal anti-inflammatory drugs (NSAIDs), statins, and corticosteroids, which alleviate inflammation through several mechanisms [4,10]. Novel therapies targeting specific cells of the immune system, for example, T-cell targeted therapies (Laquinimod, Tacrolimus, Edratide), various anti-B-cell targets (Rituximab, BLyS), and cytokine inhibitors (adalimumab, infliximab), have also been employed in disease management and treatment with varying results [11,12,13,14]. However, there is still a pressing need to develop safer and cost-effective therapeutic alternatives.…”

Section: Introductionmentioning

confidence: 99%

Potential Role of Flavonoids in Treating Chronic Inflammatory Diseases with a Special Focus on the Anti-Inflammatory Activity of Apigenin

et al. 2019

View full text Add to dashboard Cite

Inflammation has been reported to be intimately linked to the development or worsening of several non-infectious diseases. A number of chronic conditions such as cancer, diabetes, cardiovascular disorders, autoimmune diseases, and neurodegenerative disorders emerge as a result of tissue injury and genomic changes induced by constant low-grade inflammation in and around the affected tissue or organ. The existing therapies for most of these chronic conditions sometimes leave more debilitating effects than the disease itself, warranting the advent of safer, less toxic, and more cost-effective therapeutic alternatives for the patients. For centuries, flavonoids and their preparations have been used to treat various human illnesses, and their continual use has persevered throughout the ages. This review focuses on the anti-inflammatory actions of flavonoids against chronic illnesses such as cancer, diabetes, cardiovascular diseases, and neuroinflammation with a special focus on apigenin, a relatively less toxic and non-mutagenic flavonoid with remarkable pharmacodynamics. Additionally, inflammation in the central nervous system (CNS) due to diseases such as multiple sclerosis (MS) gives ready access to circulating lymphocytes, monocytes/macrophages, and dendritic cells (DCs), causing edema, further inflammation, and demyelination. As the dearth of safe anti-inflammatory therapies is dire in the case of CNS-related disorders, we reviewed the neuroprotective actions of apigenin and other flavonoids. Existing epidemiological and pre-clinical studies present considerable evidence in favor of developing apigenin as a natural alternative therapy against chronic inflammatory conditions.

show abstract

“…24 We understand that our finding of PCSK9 disruption in SLE patients, although preliminary, may open a new space of investigation in which PCSK9 could be a target in the treatment of CV disease in SLE. 25 We acknowledge the limitations that diabetes patients were included in our study. Diabetes may modify lipid profile.…”

Section: Discussionmentioning

confidence: 99%

Proprotein convertase subtilisin/kexin type 9 is related to disease activity and damage in patients with systemic erythematosus lupus

Sánchez-Pérez

Quevedo-Abeledo

Tejera-Segura

et al. 2020

Therapeutic Advances in Musculoskeletal

View full text Add to dashboard Cite

Background: Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a serine protease that regulates cholesterol metabolism through low-density lipoprotein receptor degradation and that has been linked to cardiovascular (CV) disease. The purpose of the present study was to examine whether PCSK9 levels are disrupted compared with controls in patients with systemic lupus erythematosus (SLE). We additionally sought to establish whether PCSK9 is related to both the abnormalities in the lipid profile and to the disease activity or damage of patients with SLE. Methods: We performed a cross-sectional study that encompassed 366 individuals: 195 SLE patients and 171 age-, sex-, and statin intake-matched controls. PCSK9, lipoproteins serum concentrations, and lipid profiles were assessed in patients and controls. A multivariable analysis, adjusted for standard CV risk factors, was performed to evaluate the role of PCSK9 in SLE-related dyslipidemia. Results: Most lipid related-molecules were decreased in patients with SLE compared with controls. This downregulation included PCSK9, with PCSK9 levels being lower in patients than controls in the full multivariable analysis, including the modifications in lipid profiles that the disease itself produces {beta coefficient –73 [95% confidence interval (CI) –91 to –54] ng/ml, p ⩽ 0.001}. Both SLICC and SLEDAI scores were independently and positively related to PCSK9. Patients currently on hydroxychloroquine exhibited decreased levels of PCSK9 compared with those that were not taking hydroxychloroquine [beta coefficient –30 (95% CI −54 to −6) ng/ml, p = 0.015]. Conclusion: PCSK9 is downregulated in SLE compared with controls, but SLE patients with higher disease activity and damage exhibited higher PSCK9 serum levels.

show abstract

Advances in the treatment of systemic lupus erythematosus: From back to the future, to the future and beyond

Cited by 29 publications

References 63 publications

Trends in mortality from lupus in Spain from 1980 to 2018

Trends in mortality from lupus in Spain from 1980 to 2018

Potential Role of Flavonoids in Treating Chronic Inflammatory Diseases with a Special Focus on the Anti-Inflammatory Activity of Apigenin

Proprotein convertase subtilisin/kexin type 9 is related to disease activity and damage in patients with systemic erythematosus lupus

Contact Info

Product

Resources

About